Crawford Hayley, Lumm Wendy, Leslie Alasdair, Schaefer Malinda, Boeras Debrah, Prado Julia G, Tang Jianming, Farmer Paul, Ndung'u Thumbi, Lakhi Shabir, Gilmour Jill, Goepfert Paul, Walker Bruce D, Kaslow Richard, Mulenga Joseph, Allen Susan, Goulder Philip J R, Hunter Eric
Department of Pediatrics, University of Oxford, England, UK.
J Exp Med. 2009 Apr 13;206(4):909-21. doi: 10.1084/jem.20081984. Epub 2009 Mar 23.
HLA-B57 is the class I allele most consistently associated with control of human immunodeficiency virus (HIV) replication, which may be linked to the specific HIV peptides that this allele presents to cytotoxic T lymphocytes (CTLs), and the resulting efficacy of these cellular immune responses. In two HIV C clade-infected populations in South Africa and Zambia, we sought to elucidate the role of HLA-B5703 in HIV disease outcome. HLA-B5703-restricted CTL responses select for escape mutations in three Gag p24 epitopes, in a predictable order. We show that the accumulation of these mutations sequentially reduces viral replicative capacity in vitro. Despite this, in vivo data demonstrate that there is ultimately an increase in viral load concomitant with evasion of all three HLA-B5703-restricted CTL responses. In HLA-B5703-mismatched recipients, the previously described early benefit of transmitted HLA-B5703-associated escape mutations is abrogated by the increase in viral load coincident with reversion. Rapid disease progression is observed in HLA-matched recipients to whom mutated virus is transmitted. These data demonstrate that, although costly escape from CTL responses can progressively attenuate the virus, high viral loads develop in the absence of adequate, continued CTL responses. These data underline the need for a CTL vaccine against multiple conserved epitopes.
HLA - B57是与控制人类免疫缺陷病毒(HIV)复制最密切相关的I类等位基因,这可能与该等位基因呈递给细胞毒性T淋巴细胞(CTL)的特定HIV肽段以及这些细胞免疫反应的最终效力有关。在南非和赞比亚的两个感染HIV C亚型的人群中,我们试图阐明HLA - B5703在HIV疾病转归中的作用。HLA - B5703限制性CTL反应会按可预测的顺序在三个Gag p24表位中选择逃逸突变。我们发现这些突变的积累会依次降低病毒在体外的复制能力。尽管如此,体内数据表明,最终病毒载量会增加,同时逃避了所有三种HLA - B5703限制性CTL反应。在HLA - B5703不匹配的受者中,先前描述的与传播的HLA - B5703相关逃逸突变的早期益处会因病毒载量增加及回复突变而被消除。在接受了突变病毒的HLA匹配受者中观察到疾病快速进展。这些数据表明,虽然从CTL反应中逃逸的代价高昂,会逐渐削弱病毒,但在缺乏充分持续的CTL反应时,会出现高病毒载量。这些数据强调了需要一种针对多个保守表位的CTL疫苗。